Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Adrian Newman-Tancredi

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

CHO Cells

Living Beings

Physiology

Competitive Binding

Concepts & Ideas

Drug Dose-Response Relationship

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
73
Millan, Mark
44
Cussac, Didier
34
Audinot, Valérie
23
Rivet, Jean-Michel
20
Gobert, Alain
17
Chaput, C
15
Lejeune, Françoise
15
Verrièle, Laurence
14
Assié, Marie-Bernadette
13
Depoortère, Ronan
12
Touzard, Manuelle
11
Brocco, Mauricette
11
Nicolas, Jean-Paul
10
Dekeyne, Anne
10
Bardin, Laurent

Sign-in to see all Coauthors

Publications

TOP 3
Bardin L; Malfetes N; Newman-Tancredi A; Depoortère R
Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies.
Auclair Agnès L; Kleven Mark S; Barret-Grévoz Catherine; Barreto Martine; Newman-Tancredi Adrian; Depoortère Ronan
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Bruins Slot Liesbeth A; Lestienne Fabrice; Grevoz-Barret Catherine; Newman-Tancredi Adrian; Cussac Didier
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Adrian Newman-Tancredi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Bardin L; Malfetes N; Newman-Tancredi A; Depoortère R
Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies.
Behavioural brain research 2009;205(2):360-6.
2009: Auclair Agnès L; Kleven Mark S; Barret-Grévoz Catherine; Barreto Martine; Newman-Tancredi Adrian; Depoortère Ronan
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Behavioural brain research 2009;203(2):288-95.
2009: Bruins Slot Liesbeth A; Lestienne Fabrice; Grevoz-Barret Catherine; Newman-Tancredi Adrian; Cussac Didier
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
European journal of pharmacology 2009;620(1-3):27-35.
2009: Martel J-C; Assié M-B; Bardin L; Depoortère R; Cussac D; Newman-Tancredi A
5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.
British journal of pharmacology 2009;158(1):232-42.
2009: Depoortère Ronan; Bardin Laurent; Rodrigues Michael; Abrial Erika; Aliaga Monique; Newman-Tancredi Adrian
Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Behavioural pharmacology 2009;20(4):303-11.
2009: Auclair Agnès L; Besnard Joël; Newman-Tancredi Adrian; Depoortère Ronan
The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine.
Pharmacology, biochemistry, and behavior 2009;92(2):363-9.
2009: Assié Marie-Bernadette; Mnie-Filali Ouissame; Ravailhe Véronique; Benas Christelle; Marien Marc; Bétry Cécile; Zimmer Luc; Haddjeri Nasser; Newman-Tancredi Adrian
F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
European journal of pharmacology 2009;607(1-3):74-83.
2008: Depoortère Ronan; Barret-Grévoz Catherine; Bardin Laurent; Newman-Tancredi Adrian
Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
European journal of pharmacology 2008;597(1-3):34-8.
2008: Cussac Didier; Boutet-Robinet Elisa; Ailhaud Marie-Christine; Newman-Tancredi Adrian; Martel Jean-Claude; Danty Nathalie; Rauly-Lestienne Isabelle
Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
European journal of pharmacology 2008;594(1-3):32-8.
2008: Assié Marie-Bernadette; Carilla-Durand Elisabeth; Bardin Laurent; Maraval Mireille; Aliaga Monique; Malfètes Nathalie; Barbara Michèle; Newman-Tancredi Adrian
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
European journal of pharmacology 2008;592(1-3):160-6.
2008: Newman-Tancredi Adrian; Heusler Peter; Martel Jean-Claude; Ormière Anne-Marie; Leduc Nathalie; Cussac Didier
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(3):293-307.
2008: Bruins Slot Liesbeth A; Bardin Laurent; Auclair Agnès L; Depoortere Ronan; Newman-Tancredi Adrian
Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Behavioural pharmacology 2008;19(2):145-52.
2008: Heusler Peter; Newman-Tancredi Adrian; Loock Timothé; Cussac Didier
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
European journal of pharmacology 2008;581(1-2):37-46.
2008: Millan Mark J; Mannoury la Cour Clotilde; Novi Francesca; Maggio Roberto; Audinot Valérie; Newman-Tancredi Adrian; Cussac Didier; Pasteau Valérie; Boutin Jean-A; Dubuffet Thierry; Lavielle Gilbert
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):587-99.
2007: Martel Jean-Claude; Leduc Nathalie; Ormière Anne-Marie; Faucillon Valérie; Danty Nathalie; Culie Charlène; Cussac Didier; Newman-Tancredi Adrian
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors.
European journal of pharmacology 2007;574(1):15-9.
2007: Maurel Jean Louis; Autin Jean-Marie; Funes Philippe; Newman-Tancredi Adrian; Colpaert Francis; Vacher Bernard
High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.
Journal of medicinal chemistry 2007;50(20):5024-33.
2007: Rauly-Lestienne Isabelle; Boutet-Robinet Elisa; Ailhaud Marie-Christine; Newman-Tancredi Adrian; Cussac Didier
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Naunyn-Schmiedeberg's archives of pharmacology 2007;376(1-2):93-105.
2007: Newman-Tancredi Adrian; Cussac Didier; Depoortere Ronan
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Current opinion in investigational drugs (London, England : 2000) 2007;8(7):539-54.
2007: Auclair Agnès L; Galinier Alexandra; Besnard Joël; Newman-Tancredi Adrian; Depoortère Ronan
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
Psychopharmacology 2007;193(1):45-54.
2007: Assié Marie-Bernadette; Bardin Laurent; Auclair Agnès; Consul-Denjean Nathalie; Sautel François; Depoortère Ronan; Newman-Tancredi Adrian
F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
Naunyn-Schmiedeberg's archives of pharmacology 2007;375(4):241-50.
2007: Newman-Tancredi A; Assié M-B; Martel J-C; Cosi C; Slot L Bruins; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
British journal of pharmacology 2007;151(2):237-52.
2007: Depoortère R; Bardin L; Auclair A L; Kleven M S; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
British journal of pharmacology 2007;151(2):253-65.
2007: Depoortère R; Auclair A L; Bardin L; Bruins Slot L; Kleven M S; Colpaert F; Vacher B; Newman-Tancredi A
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
British journal of pharmacology 2007;151(2):266-77.
2007: Bardin Laurent; Auclair Agnès; Kleven Mark S; Prinssen Eric P M; Koek Wouter; Newman-Tancredi Adrian; Depoortère Ronan
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Behavioural pharmacology 2007;18(2):103-18.
2007: Heusler Peter; Newman-Tancredi Adrian; Castro-Fernandez Annabelle; Cussac Didier
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Neuropharmacology 2007;52(4):1106-13.
2007: Martel Jean-Claude; Ormière Anne-Marie; Leduc Nathalie; Assié Marie-Bernadette; Cussac Didier; Newman-Tancredi Adrian
Native rat hippocampal 5-HT1A receptors show constitutive activity.
Molecular pharmacology 2007;71(3):638-43.
2007: Cuisiat Stephane; Bourdiol Nathalie; Lacharme Vincent; Newman-Tancredi Adrian; Colpaert Francis; Vacher Bernard
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Journal of medicinal chemistry 2007;50(4):865-76.
2006: Assié Marie-Bernadette; Dominguez Hélène; Consul-Denjean Nathalie; Newman-Tancredi Adrian
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Naunyn-Schmiedeberg's archives of pharmacology 2006;373(6):441-50.
2006: Assié M-B; Lomenech H; Ravailhe V; Faucillon V; Newman-Tancredi A
Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat.
British journal of pharmacology 2006;149(2):170-8.
2006: Auclair Agnès L; Kleven Mark S; Besnard Joël; Depoortère Ronan; Newman-Tancredi Adrian
Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):1900-9.
2006: Bardin Laurent; Kleven Mark S; Barret-Grévoz Catherine; Depoortère Ronan; Newman-Tancredi Adrian
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):1869-79.
2006: Cosi Cristina; Carilla-Durand Elisabeth; Assié Marie Bernadette; Ormiere Anne Marie; Maraval Mireille; Leduc Nathalie; Newman-Tancredi Adrian
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
European journal of pharmacology 2006;535(1-3):135-44.
2006: Bruins Slot Liesbeth A; De Vries Luc; Newman-Tancredi Adrian; Cussac Didier
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
European journal of pharmacology 2006;534(1-3):63-70.
2005: Bruins Slot Liesbeth A; Kleven Mark S; Newman-Tancredi Adrian
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Neuropharmacology 2005;49(7):996-1006.
2005: Heusler Peter; Pauwels Petrus J; Wurch Thierry; Newman-Tancredi Adrian; Tytgat Jan; Colpaert Francis C; Cussac Didier
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.
Neuropharmacology 2005;49(7):963-76.
2005: Assié M-B; Consul-Denjean N; Koek W; Newman-Tancredi A
Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex.
Pharmacology 2005;75(2):63-8.
2005: Assié Marie-Bernadette; Ravailhe Véronique; Faucillon Valérie; Newman-Tancredi Adrian
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
The Journal of pharmacology and experimental therapeutics 2005;315(1):265-72.
2005: Newman-Tancredi Adrian; Assié Marie-Bernadette; Leduc Nathalie; Ormière Anne-Marie; Danty Nathalie; Cosi Cristina
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005;8(3):341-56.
2005: Kleven Mark S; Barret-Grévoz Catherine; Bruins Slot Liesbeth; Newman-Tancredi Adrian
Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Neuropharmacology 2005;49(2):135-43.
2005: Cosi Cristina; Waget Aurelie; Rollet Karin; Tesori Valentina; Newman-Tancredi Adrian
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Brain research 2005;1043(1-2):32-41.
2005: Bardin Laurent; Assié Marie-Bernadette; Pélissou Martine; Royer-Urios Isabelle; Newman-Tancredi Adrian; Ribet Jean-Paul; Sautel François; Koek Wouter; Colpaert Francis C
Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1034-42.
2005: Kleven Mark S; Assié Marie-Bernadette; Cosi Cristina; Barret-Grévoz Catherine; Newman-Tancredi Adrian
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.
Psychopharmacology 2005;177(4):373-80.
2004: Millan Mark J; Cussac Didier; Gobert Alain; Lejeune Françoise; Rivet Jean-Michel; Mannoury La Cour Clotilde; Newman-Tancredi Adrian; Peglion Jean-Louis
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):903-20.
2003: Newman-Tancredi A; Rivet J-M; Cussac D; Touzard M; Chaput C; Marini L; Millan M J
Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Naunyn-Schmiedeberg's archives of pharmacology 2003;368(3):188-99.
2003: Millan M J; Gobert A; Lejeune F; Dekeyne A; Newman-Tancredi A; Pasteau V; Rivet J-M; Cussac D
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
The Journal of pharmacology and experimental therapeutics 2003;306(3):954-64.
2003: Newman-Tancredi Adrian; Cussac Didier; Marini Laetitia; Touzard Manuelle; Millan Mark J
h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.
British journal of pharmacology 2003;138(6):1077-84.
2002: Newman-Tancredi Adrian; Cussac Didier; Quentric Yann; Touzard Manuelle; Verrièle Laurence; Carpentier Nathalie; Millan Mark J
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):815-22.
2002: Newman-Tancredi Adrian; Cussac Didier; Audinot Valérie; Nicolas Jean-Paul; De Ceuninck Frédéric; Boutin Jean-A; Millan Mark J
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
The Journal of pharmacology and experimental therapeutics 2002;303(2):805-14.
2002: Millan Mark J; Maiofiss Lisa; Cussac Didier; Audinot Valérie; Boutin Jean-A; Newman-Tancredi Adrian
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):791-804.
2002: Audinot Valérie; Fabry Nelly; Nicolas Jean-Paul; Beauverger Philippe; Newman-Tancredi Adrian; Millan Mark J; Try Anne; Bornancin Frédéric; Canet Emmanuel; Boutin Jean A
Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors.
Cellular signalling 2002;14(10):829-37.
2002: Newman-Tancredi Adrian; Cussac Didier; Marini Laetitia; Millan Mark J
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
Molecular pharmacology 2002;62(3):590-601.
2002: Cussac Didier; Newman-Tancredi Adrian; Duqueyroix Delphine; Pasteau Valérie; Millan Mark J
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Molecular pharmacology 2002;62(3):578-89.
2002: Cussac Didier; Duqueyroix Delphine; Newman-Tancredi Adrian; Millan Mark J
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Psychopharmacology 2002;162(2):168-77.
2002: Millan M J; Newman-Tancredi A; Lochon S; Touzard M; Aubry S; Audinot V
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
Pharmacology, biochemistry, and behavior 2002;71(4):589-98.
2002: Cussac Didier; Newman-Tancredi Adrian; Quentric Yann; Carpentier Nathalie; Poissonnet Guillaume; Parmentier Jean-Gilles; Goldstein Solo; Millan Mark J
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(3):242-52.
2002: Peglion Jean-Louis; Goument Bertrand; Despaux Nicole; Charlot Valérie; Giraud Hélène; Nisole Christian; Newman-Tancredi Adrian; Dekeyne Anne; Bertrand Marc; Genissel Patrick; Millan Mark J
Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.
Journal of medicinal chemistry 2002;45(1):165-76.
2001: Newman-Tancredi A; Cussac D; Brocco M; Rivet J M; Chaput C; Touzard M; Pasteau V; Millan M J
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra.
Brain research 2001;920(1-2):41-54.
2001: Newman-Tancredi A; Verrièle L; Touzard M; Millan M J
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
European journal of pharmacology 2001;428(2):177-84.
2001: Audinot V; Newman-Tancredi A; Cussac D; Millan M J
Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(3):410-22.
2001: Millan M J; Gobert A; Lejeune F; Newman-Tancredi A; Rivet J M; Auclair A; Peglion J L
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
The Journal of pharmacology and experimental therapeutics 2001;298(2):565-80.
2001: Millan M J; Newman-Tancredi A; Duqueyroix D; Cussac D
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
European journal of pharmacology 2001;424(1):13-7.
2001: Millan M J; Newman-Tancredi A; Quentric Y; Cussac D
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors.
Psychopharmacology 2001;156(1):58-62.
2001: Millan M J; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet J M; Brocco M; Duqueyroix D; Nicolas J P; Boutin J A; Newman-Tancredi A
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
The Journal of pharmacology and experimental therapeutics 2001;297(3):876-87.
2001: Newman-Tancredi A; Chaput C; Touzard M; Millan M J
Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(4):391-8.
2001: Cordi A A; Berque-Bestel I; Persigand T; Lacoste J M; Newman-Tancredi A; Audinot V; Millan M J
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
Journal of medicinal chemistry 2001;44(5):787-805.
2001: Newman-Tancredi A; Verrièle L; Millan M J
Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
British journal of pharmacology 2001;132(2):518-24.
2001: Audinot V; Newman-Tancredi A; Millan M J
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms.
Neuropharmacology 2001;40(1):57-64.
2000: Millan M J; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin J A; Nicolas J P; Renouard-Try A; Lacoste J M; Cordi A
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1192-205.
2000: Newman-Tancredi A; Audinot V; Moreira C; Verrièle L; Millan M J
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
Molecular pharmacology 2000;58(5):1042-9.
2000: Millan M J; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet J M; Audinot V; Dubuffet T; Lavielle G
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1048-62.
2000: Gobert A; Rivet J M; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas J P; Cistarelli L; Melon C; Millan M J
Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Synapse (New York, N.Y.) 2000;36(3):205-21.
2000: Cussac D; Newman-Tancredi A; Sezgin L; Millan M J
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):569-72.
2000: Cussac D; Newman-Tancredi A; Nicolas J P; Boutin J A; Millan M J
Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):549-54.
2000: Cussac D; Newman-Tancredi A; Sezgin L; Millan M J
The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
European journal of pharmacology 2000;394(1):47-50.
2000: Newman-Tancredi A; Chaput C; Touzard M; Millan M J
[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum.
Neuropharmacology 2000;39(6):1111-3.
2000: Millan M J; Gobert A; Rivet J M; Adhumeau-Auclair A; Cussac D; Newman-Tancredi A; Dekeyne A; Nicolas J P; Lejeune F
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
The European journal of neuroscience 2000;12(3):1079-95.
2000: Morris B J; Newman-Tancredi A; Audinot V; Simpson C S; Millan M J
Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons.
Journal of neuroscience research 2000;59(6):740-9.
2000: Cussac D; Newman-Tancredi A; Quentric Y; Millan M J
An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(2):221-3.
2000: Millan M J; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas J P; Cogé F; Galizzi J P; Boutin J A; Rivet J M; Dekeyne A; Gobert A
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Synapse (New York, N.Y.) 2000;35(2):79-95.
2000: Millan M J; Brocco M; Rivet J M; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion J L; Dekeyne A
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 2000;292(1):54-66.
2000: Millan M J; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet J M; Audinot V; Adhumeau A; Brocco M; Nicolas J P; Boutin J A; Despaux N; Peglion J L
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
The Journal of pharmacology and experimental therapeutics 2000;292(1):38-53.
2000: Carato P; Depreux P; Lesieur D; Millan M; Newman-Tancredi A; Rettori M C; Caignard D H
Synthesis and binding studies on a new series of arylpiperazino benzazol-2-one and benzoxazin-3-one derivatives as selective D4 ligands.
Drug design and discovery 2000;17(2):173-81.
1999: Millan M J; Brocco M; Gobert A; Joly F; Bervoets K; Rivet J; Newman-Tancredi A; Audinot V; Maurel S
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.
The European journal of neuroscience 1999;11(12):4419-32.
1999: Newman-Tancredi A; Rivet J; Chaput C; Touzard M; Verrièle L; Millan M J
The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study.
European journal of pharmacology 1999;384(2-3):111-21.
1999: Cussac D; Newman-Tancredi A; Pasteau V; Millan M J
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism.
Molecular pharmacology 1999;56(5):1025-30.
1999: Millan M J; Gobert A; Audinot V; Dekeyne A; Newman-Tancredi A
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2 Suppl):61S-67S.
1999: Dubuffet T; Newman-Tancredi A; Cussac D; Audinot V; Loutz A; Millan M J; Lavielle G
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters 1999;9(14):2059-64.
1999: Newman-Tancredi A; Cussac D; Audinot V; Millan M J
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):447-53.
1999: Newman-Tancredi A; Cussac D; Audinot V; Pasteau V; Gavaudan S; Millan M J
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Molecular pharmacology 1999;55(3):564-74.
1998: Newman-Tancredi A; Chaput C; Touzard M; Verrièle L; Millan M J
Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535.
Annals of the New York Academy of Sciences 1998;861():263-4.
1998: Audinot V; Newman-Tancredi A; Gobert A; Rivet J M; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan M J
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
The Journal of pharmacology and experimental therapeutics 1998;287(1):187-97.
1998: Millan M J; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet J M; Schreiber R; Dekeyne A; Spedding M; Nicolas J P; Peglion J L
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
The Journal of pharmacology and experimental therapeutics 1998;287(1):167-86.
1998: Millan M J; Schreiber R; Dekeyne A; Rivet J M; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1356-73.
1998: Millan M J; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet J M; Cussac D; Nicolas J P; Muller O; Lavielle G
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1341-55.
1998: Newman-Tancredi A; Gavaudan S; Conte C; Chaput C; Touzard M; Verrièle L; Audinot V; Millan M J
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
European journal of pharmacology 1998;355(2-3):245-56.
1998: Newman-Tancredi A; Nicolas J P; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan M J
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1998;358(2):197-206.
1998: Spedding M; Newman-Tancredi A; Millan M J; Dacquet C; Michel A N; Jacoby E; Vickery B; Tallentire D
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat.
Neuropharmacology 1998;37(6):769-80.
1998: Gobert A; Rivet J M; Audinot V; Newman-Tancredi A; Cistarelli L; Millan M J
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.
Neuroscience 1998;84(2):413-29.
1998: Newman-Tancredi A; Chaput C; Gavaudan S; Verrièle L; Millan M J
Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;18(5):395-8.
1998: Newman-Tancredi A; Verrièle L; Chaput C; Millan M J
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
Naunyn-Schmiedeberg's archives of pharmacology 1998;357(3):205-17.
1997: Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan M J
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 1997;282(1):181-91.
1997: Millan M J; Newman-Tancredi A; Rivet J M; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
The Journal of pharmacology and experimental therapeutics 1997;282(1):132-47.
1997: Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan M J
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Naunyn-Schmiedeberg's archives of pharmacology 1997;355(6):682-8.
1997: Audinot V; Lochon S; Newman-Tancredi A; Lavielle G; Millan M J
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine.
European journal of pharmacology 1997;327(2-3):247-56.
1997: Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Millan M J
Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry.
Neuropharmacology 1997;36(4-5):451-9.
1997: Newman-Tancredi A; Conte C; Chaput C; Spedding M; Millan M J
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635.
British journal of pharmacology 1997;120(5):737-9.
1997: Lejeune F; Newman-Tancredi A; Audinot V; Millan M J
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1241-9.
1997: Newman-Tancredi A; Audinot-Bouchez V; Gobert A; Millan M J
Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors.
European journal of pharmacology 1997;319(2-3):379-83.
1996: Newman-Tancredi A; Chaput C; Verrièle L; Millan M J
S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
European journal of pharmacology 1996;307(1):107-11.
1996: Newman-Tancredi A; Chaput C; Verriele L; Millan M J
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.
Neuropharmacology 1996;35(1):119-21.
1996: Newman-Tancredi A; Verrièle L; Chaput C; Millan M J
Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation.
Brain research bulletin 1996;41(2):93-6.
1995: Newman-Tancredi A; Audinot V; Jacques V; Peglion J L; Millan M J
[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.
Neuropharmacology 1995;34(12):1693-6.
1995: Millan M J; Peglion J L; Vian J; Rivet J M; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
The Journal of pharmacology and experimental therapeutics 1995;275(2):885-98.
1995: Millan M J; Audinot V; Melon C; Newman-Tancredi A
Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia.
European journal of pharmacology 1995;280(2):225-9.
1995: Millan M J; Rivet J M; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1418-27.
1995: Gobert A; Lejeune F; Rivet J M; Audinot V; Newman-Tancredi A; Millan M J
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1032-46.
1993: Sundaram H; Newman-Tancredi A; Strange P G
Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms.
Biochemical pharmacology 1993;45(5):1003-9.
1992: Newman-Tancredi A; Wootton R; Strange P G
High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
The Biochemical journal 1992;285 ( Pt 3)():933-8.
1992: Sundaram H; Newman-Tancredi A; Strange P G
Pharmacological characterisation of the 5-HT1A serotonin receptor using the agonist [3H]8-OH-DPAT, and the antagonist [3H]spiperone.
Biochemical Society transactions 1992;20(2):145S.
1991: Newman-Tancredi A; Strange P G
High level expression of serotonin (5HT-1a) receptor in animal cells.
Biochemical Society transactions 1991;19(2):144S.

Sign-in to see more